Maze Therapeutics IPOs at $487M, targeting APOL1 Kidney Disease with MZE829 in Phase 2. Click here to read an analysis of MAZE stock now.

The liver is a vital organ, crucial to digestion, metabolism and the elimination of toxins. It has a unique ability, ...

Life has evolved over billions of years, adapting to the changing environment. Similarly, enzymes—proteins that speed up ...

A new study provides fresh insight into traditional acid-base chemistry by revealing that the mutual neutralization of isolated hydronium (H₃O⁺) and ...

Two LED lamps installed in the solar chamber simulated solar radiation, allowing solar photodecomposition to occur under controlled conditions. The BTEX solutions were prepared and diluted in ...

Enzymes originally evolved in high-temperature environments and later adapted to lower temperatures as Earth cooled. Scientists discovered that a key shift in enzyme function occurred over ...

While biodiesel provides a cleaner-burning alternative to petroleum diesel, it produces CO2 and hazardous wastewater during ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...